News EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 Staff September 11, 2023 Iframe sync Post navigation Previous: Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive OfficerNext: Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer More Stories Healthcare Medicaid Medicare News Nutrition Pharmaceutical CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD Staff December 22, 2025 Diagnostics Fitness News Private Wellness Club Continuum Unlocks Final Membership Tier at West Village Flagship Staff December 22, 2025 Cancer Diagnostics DNA News Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach Staff December 22, 2025
